Tonix Pharmaceuticals presents new data on TNX-102 SL treatment

Tonix Pharmaceuticals (TNXP) presented data in an oral presentation at the 7th International Congress on Controversies in Fibromyalgia, held March 3-4, 2025, in Vienna, Austria. TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia. TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two double-blind randomized Phase 3 studies. FDA Prescription Drug User Fee Act goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia. If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years